Nasal sprays could be the future of treatment for Parkinson’s disease
Scientists at the University of York have made significant progress in the development of a nasal spray treatment for patients with Parkinson’s disease.
Researchers have developed a new gel that can adhere to tissue inside the nose alongside the drug levodopa, helping deliver treatment directly to the brain.
Levodopa is converted to dopamine in the brain, which makes-up for the deficit of dopamine-producing cells in Parkinson’s patients, and helps treat the symptoms of the disease. Over extended periods of time, however, levodopa becomes less effective, and increased doses are needed.
Professor David Smith, from the University of York’s Department of Chemistry, said: “The current drug used for Parkinson’s Disease is effective to a point, but after a long period of use the body starts to breakdown the drug before it gets to the brain where it is most needed.
“This means increased dosage is necessary, and in later stages, sometimes, instead of tablets, the drug has to be injected. Investigations into nasal sprays have long been of interest as a more effective delivery because of its direct route to the brain via the nerves that service the nose, but the challenge here is to find a way of making it adhere to the nasal tissue long enough to release a good dosage of the drug.”
The researchers created a gel, loaded with levodopa, that could flow into the nose as a liquid and then rapidly change to a thin layer of gel inside the nose. The method was tested in animal models by a team at King’s College London, where levodopa was successfully released from the gel into the blood and directly to the brain.
Professor Smith said: “The results indicated that the gel gave the drug better adhesion inside the nose, which allowed for better levels of uptake into both the blood and brain.”
The team are now working to incorporate these materials in nasal spray devices to progress to clinical trials in humans. The approach may also be relevant to other neurodegenerative diseases such as Alzheimer’s.
Khuloud Al-Jamal, Professor of Drug Delivery and Nanomedicine from King’s College London, said: “Not only did the gel perform better than a simple solution, but the brain uptake was better than that achieved using intravenous injection of the drug. This suggests that nasal delivery of Parkinson’s drugs using this type of gel may have clinical relevance.”
Original Article: Step-closer to nasal spray drug delivery for Parkinson’s disease
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Nasal spray drug delivery
- Your Next COVID Vaccination Could Be a Nasal Spray: Here's Why
Researchers are working on a new approach to COVID-19 vaccination that will be delivered in the form of a nasal spray, which may ... various aspects of nasal delivery, and human testing must ...
- Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
XHANCE ® (fluticasone propionate) nasal spray is a drug-device combination product combining its proprietary Exhalation Delivery System™ (EDS™) designed to uniquely deliver drug high and deep ...
- Nasal spray highly effective against HIV and SARS-CoV-2 in animal models
and nasal-associated lymphoid tissue (NALT). One of the key challenges associated with mucosal vaccines is the delivery of vaccine components across mucosal barriers. Restricted uptake of vaccines ...
- Nasal Spray Packaging Market to Witness Remarkable Growth by 2030
the demand for nasal spray packaging is anticipated to boost during the forecast period, owing to increasing demand for high-end multi-dose nasal drug delivery solutions. Due to the high ...
- Platform for enhanced drug delivery
BENGALURU: Synergia Biosciences has developed a nano-emulsion intra-nasal platform for enhanced drug delivery to the central ... Synergia. A nasal spray is more potent and would need a small ...
Go deeper with Google Headlines on:
Nasal spray drug delivery
Go deeper with Bing News on:
- FDA turns down Acadia Pharma drug for Alzheimer’s psychosis; new trial needed
Acadia Pharmaceuticals drug Nuplazid failed to win FDA approval for the treatment of psychosis in Alzheimer’s disease patients. The regulator said that the data submitted were not from an adequate and ...
- Israeli study showing higher Parkinson’s disease risk in PTSD patients bolsters research on US veterans
Researchers in Israel have found that post-traumatic stress disorder may be associated with an increased risk of Parkinson’s disease, buttressing a previous study of U.S. veterans of Iraq and ...
- Monoclonal Antibodies No Better Than Placebo for Early Parkinson Disease
The monoclonal antibodies cinpanemab and prasinezumab show almost no benefit for early Parkinson disease, according to two phase 2 trials published in the ...
- Meridian woman rides 8,000 miles for Parkinson’s Disease
Joni Pursell took her motorcycle across the country and back to honor those dealing with Parkinson’s disease. MERIDIAN, Idaho — Joni Pursell has been riding her motorcycle for many years now. She ...
- Nanobody has potential to treat Parkinson's disease
Researchers from Johns Hopkins create a nanobody capable of penetrating brain cells and preventing misshapen proteins from spreading, halting the progression of neurocognitive diseases ...